Current application of chimeric antigen receptor T cell immunotherapy and related laboratory examinations / 中华检验医学杂志
Chinese Journal of Laboratory Medicine
; (12): 871-874, 2022.
Article
em Zh
| WPRIM
| ID: wpr-958593
Biblioteca responsável:
WPRO
ABSTRACT
Chimeric antigen receptor (CAR)-T cell immunotherapy is a revolutionary advancement in cancer treatment, and is highly effective in treatment of B cell leukemia, lymphoma, and multiple myeloma. However, it has some deficiencies such as antigen escape, antigen heterogeneity, toxic and side effects, which also pose challenges for therapy of other hematological malignancies and solid tumors. Comprehensive and continuous laboratory monitoring before and after CAR-T cell immunotherapy plays an important role in early warning of toxic and side effects, as well as theraputic evaluation. In the future, new breakthroughs for tumor therapy. Should be focused on improving CAR-T cells design, enhancing their anti-tumor activity, and optimizing therapeutic regimen.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Laboratory Medicine
Ano de publicação:
2022
Tipo de documento:
Article